Skip to main content
SpringerLink
Log in

90Y Ibritumomab Tiuxetan

  • Adis New Drug Profile
  • Published:
American Journal of Cancer

Abstract

▴ 90Yttrium (90Y) ibritumomab tiuxetan is a radiolabeled murine anti-CD20 monoclonal antibody that binds specifically to the CD20 antigen on normal and malignant B lymphocytes. It has antitumor activity as a result of emission of β particles. It is administered as part of a therapeutic regimen which includes rituximab, a monoclonal antibody which produces antibody-dependent cell-and complement-mediated cytotoxicity.

▴ 90Y ibritumomab tiuxetan, when given as part of the recommended regimen, produced significantly higher overall (80 vs 56%: p = 0.002) and complete response rates (30 vs 16%: p = 0.04) than rituximab alone in a randomized nonblind study in patients with relapsed or refractory low-grade, follicular or transformed non-Hodgkin’s lymphoma (NHL). Quality of life, as measured by the Functional Assessment of Cancer Therapy-General survey, was also improved significantly (from baseline to week 12; p = 0.001) in recipients of ibritumomab tiuxetan but not in rituximab recipients.

▴ In a noncomparative trial in patients with follicular NHL refractory to rituximab, the ibritumomab tiuxetan therapeutic regimen produced overall and complete response rates of 74 and 15%, respectively.The Kaplan-Meier median estimates of the time to progression and duration of response were 6.8 and 6.4 months, respectively.

▴ The dose-limiting toxicity of ibritumomab tiuxetan is reversible myelosuppression which was seen in most patients. Most non-hematological toxicity was mild or moderate.

Features and properties of 90Y Ibritumomab Tiuxetan

90Y Ibritumomab Tiuxetan

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999 Jul; 58: 79–88

    Article  PubMed  CAS  Google Scholar 

  2. Krasner C, Joyce RM. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin’s lymphoma.CurrPharmBiotechnol 2001 Dec; 2(4): 341–9

    CAS  Google Scholar 

  3. Alcindor T, Witzig TE. Radioimmunotherapy with Yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin’s lymphoma. Curr Treat Options Oncol 2002 Aug; 3(4): 275–82

    Article  PubMed  Google Scholar 

  4. DeNardo GL, O’Donnell RT, Oldham RK, et al. A revolution in the treatment of non-Hodgkin’s lymphoma. Cancer Biother Radiopharm 1998; 13(4): 213–23

    Article  PubMed  CAS  Google Scholar 

  5. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium- 90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immu-notherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002 May 15; 20(10): 2453–63

    Article  PubMed  CAS  Google Scholar 

  6. Wun T, Kwon DS, Tuscano JM. Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgkin’s lymphoma. Biodrugs 2001; 15(3): 151–62

    Article  PubMed  CAS  Google Scholar 

  7. Bush S. Monoclonal antibodies conjugated with radioisotopes for the treatment of non-Hodgkin’s lymphoma. Semin Oncol Nurs 2002 Feb; 18(1 Suppl. 1): 16–21

    Article  PubMed  Google Scholar 

  8. Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol 1999 Sep; 11: 375–80

    Article  PubMed  CAS  Google Scholar 

  9. IDEC Pharmaceuticals Corporation. Zevalin: product information. San Diego (CA): IDEC Pharmaceuticals Corporation, 2002 Jan

    Google Scholar 

  10. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-1 abeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2(3): 457–70

    PubMed  CAS  Google Scholar 

  11. Wiseman GA, Gordon LI, Witzig TE, et al. Zevalin radioimmunotherapy is not associated with significant or prolonged depletion of T cells or natural killer cells [abstract]. Blood 2000 Nov 16; 96 (Pt 2): 252

    Google Scholar 

  12. Chinn PC, Leonard JE, Rosenberg J, et al. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin’s lymphoma. Int J Oncol 1999 Nov; 15(5): 1017–25

    PubMed  CAS  Google Scholar 

  13. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol 2001 Jul; 39: 181–94

    Article  PubMed  CAS  Google Scholar 

  14. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999 Dec; 17(12): 3793–803

    PubMed  CAS  Google Scholar 

  15. Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 2000 Jul; 27(7): 766–77

    Article  PubMed  CAS  Google Scholar 

  16. Wiseman GA, Leigh BR, Czuczman MS, et al. The pharmacokinetic profile of Zevalin TM is similar when radiolabeled with 90Y from different suppliers [abstract]. Blood 2001 Nov 16; 98 (Pt 2): 254

    Google Scholar 

  17. Wiseman GA, Leigh B, Erwin WD, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002 Feb 15; 94(4 Suppl.): 1349–57

    Article  PubMed  CAS  Google Scholar 

  18. IDEC Pharmaceuticals. Product: Zevalin [online]. Available from URL: http://www.idecpharm.com/site/science/zevalin.htm [Accessed 2002 May 13]

  19. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002 Jun 15; 99(12): 4336–42

    Article  PubMed  CAS  Google Scholar 

  20. Witzig TE, White CA, Flinn IW, et al. Zevalin (TM) radioimmunotherapy of rituximab-refractory follicular non-Hodgkin’s lymphoma [abstract]. Blood 2000 Nov 16; 96 (Pt 1): 507

    Google Scholar 

  21. Witzig TE. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin’s lymphoma. Semin Oncol 2000 Dec; 27(6 Suppl. 12): 74–8

    PubMed  CAS  Google Scholar 

  22. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas: NCI Sponsored International Working Group [abstract]. J Clin Oncol 1999 Apr; 17(4): 1244

    PubMed  CAS  Google Scholar 

  23. Witzig T, White CA, Wiseman G, et al. IDEC-Y2B8 radioimmunotherapy: responses in patients with splenomegaly [abstract]. Blood 1998 Nov 15; 92 (Pt 1 Suppl. 1): 417

    Google Scholar 

  24. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002 Aug 1; 20(15): 3262–9

    Article  PubMed  CAS  Google Scholar 

  25. Harris NL, Jaffe ES, Stein H, et al. A revised Europe an-American classification of lymphoid neoplasms: a proposal fromme International Lymphoma Study Group. Blood 1994 Sep 1; 84(5): 1361–92

    PubMed  CAS  Google Scholar 

  26. Emmanoulidies C, Witzig T, Gordon L, et al. Zevalin radioimmunotherapy is safe and effective in geriatric patients with low grade, follicular or CD20+ transformed non-Hodgkin’s lymphoma [plus poster]. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12–15; San Francisco, 286

  27. Schilder R, Witzig T, Gordon L, et al. Zevalin radioimmunotherapy for low grade, follicular, and Cd20+ transformed non-Hodgkin’s lymphoma is effective even in patients with mild thrombocytopena and poor prognostic factors. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12–15; San Francisco, 236

  28. Witzig TE, Gordon L, Gaston I, et al. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy of follicular NHL: results by follicular subtype [abstract]. Proc ASCO 2002; 21: 1063a

    Google Scholar 

  29. Bartlett NL, Witzig TE, Gordon L, et al. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B cell non-Hodgkin’s lymphoma (NHL) patients [abstract]. Proc ASCO 2002; 21: 51a

    Google Scholar 

  30. Gordon LI, Witzig TE, Emmanouilides CE, et al. 90Y ibritumomab (Zevalin) in aggressive non-Hodgkin’s lymphoma: analysis of response and toxicity [abstract]. Proc ASCO 2002 May; 21 (Pt 1): 1061a

    Google Scholar 

  31. Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with Zevalin TM for non-Hodgkin lymphoma. Blood 2001 Nov 16; 98 (Pt 1): 604–5

    Article  Google Scholar 

  32. Czuczman MS, Emmanouilides CE, Witzig TE, et al. Multivariate analysis of prognostic factors correlated with response to Y90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkins lymphoma [abstract]. Proc ASCO 2002; 21: 1062a

    Google Scholar 

  33. Witzig TE, White CA, Gordon LI, et al. Zevalin TM radioimmunotherapy can be safely administered to patients with relapsed or refractory, B cell non-Hodgkin’s lymphoma [abstract]. Blood 2001 Nov 16; 98 (Pt 1): 606

    Google Scholar 

  34. D’Orazio AI, Fisher MD. Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma and chronic lymphocytic leukemia. Clin Lymphoma 2001; 2(3): 139–44

    Article  PubMed  Google Scholar 

  35. Wiseman GA, Leigh BR, Witzig TE, et al. Family members of patients receiving Zevalin TM radioimmunotherapy do not receive radiation exposure above background levels. Blood 2001 Nov 16; 98 (Pt 2): 236–7

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Inc., 860 Town Center Drive, Langhorne, PA, 19047, USA

    Christopher I. Carswell & Lynda R. Wiseman

Authors
  1. Christopher I. Carswell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lynda R. Wiseman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher I. Carswell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carswell, C.I., Wiseman, L.R. 90Y Ibritumomab Tiuxetan. Am J Cancer 1, 341–348 (2002). https://doi.org/10.2165/00024669-200201050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200201050-00004

Keywords

Search

Navigation